Work

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.3003

Authors: Marwan Fakih, Bert O'Neil, Timothy Jay Price, Gerald Steven Falchook, Jayesh Desai, James Kuo, Ramaswamy Govindan, Erik Rasmussen, Phuong Khanh H. Morrow, Jude Ngang, Haby A. Henary, David S. Hong

Institutions: City Of Hope National Medical Center, City of Hope, Indiana University School of Medicine, Queen Elizabeth Hospital, The University of Adelaide, HealthONE, Peter MacCallum Cancer Centre, Washington University in St. Louis, Alvin J. Siteman Cancer Center, Amgen (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947477797

Cites:

Cited by: 170

Related to: 10